115294-32-1

Usage

Uses

1. Used in Pharmaceutical Synthesis:
C₂₈H₂₀Cl₄N₂O is used as a reactant in the synthesis of enantio-enriched (-)-nutlin-3, a compound with potential applications in the pharmaceutical industry. The synthesis of (-)-nutlin-3 involves the use of C₂₈H₂₀Cl₄N₂O as a key intermediate, highlighting its importance in the development of new drugs and therapeutic agents.
2. Used in Chemical Research:
As a chemical intermediate, C₂₈H₂₀Cl₄N₂O is also utilized in various research applications, particularly in the field of organic chemistry. It can be employed to study the properties and reactivity of similar compounds, as well as to develop new synthetic methods and strategies for the preparation of complex organic molecules.
3. Used in Material Science:
The compound may also find applications in material science, where it could be used to develop new materials with specific properties. The unique structure of C₂₈H₂₀Cl₄N₂O, with its multiple chlorine and nitrogen atoms, may contribute to the development of materials with enhanced properties, such as improved stability or reactivity.

Upstream product

• 104-88-1 4-chlorobenzaldehyde 
• 631-61-8 ammonium acetate 

Relevant academic research and scientific papers

Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents

p53-Murine double minute 2 (MDM2) interaction and histone deacetylases (HDACs) are important targets in antitumor drug development. Inspired by the synergistic effects between MDM2 and HDACs, the first MDM2/HDACs dual inhibitors were identified, which sho

Dimer amide micromolecule PROTACs for inducing MDM2 to self-degrade E3 ubiquitin ligase

The invention provides dimer amide micromolecule PROTACs for inducing MDM2 to self-degrade E3 ubiquitin ligase. The structure of the PROTACs is shown in the specification, wherein in a compound (I), L1 is C1-C30 linear or branched alkyl with or without a substituent group, and any carbon atom in L1 is optionally replaced by heteroatom; R1, R2, R3 and R4 are C1-C30 linear or branched alkyl with orwithout a substituent group, C1-C30 aryl with or without a substituent group, C1-C30 linear or branched alkylaryl with or without a substituent group or C1-C30 linear or branched aryl alkyl with or without a substituent group respectively and independently; X1, X2, X3 and X4 are halogen respectively and independently.

Design, synthesis and CoMFA studies of N1-amino acid substituted 2,4,5-triphenyl imidazoline derivatives as p53-MDM2 binding inhibitors

A series of novel N1-amino-acid substituted 2,4,5-triphenyl imidazoline derivatives was designed and synthesized based on our previous studies. All synthesized target compounds were screened for their p53-MDM2 binding inhibitory activities and anti-proliferative activities against five cancer cell lines. Among them, twelve compounds displayed improved binding inhibitory activities and most compounds showed higher cell growth inhibition activities with IC 50 values in the low micromolar range. Compound 6c exhibited marked p53-MDM2 binding inhibitory activity (IC50 = 0.59 μM) which was eightfold more potent than that of Nutlin-1 (IC50 = 4.78 μM). CoMFA analysis was performed based on obtained biological data and resulted in a statistically significant CoMFA model with high predict abilities (q 2 = 0.645, r2 = 0.979).

Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors

Three series of novel imidazoline derivatives were designed, synthesized, and evaluated for their p53-MDM2 binding inhibitory activities, and anti-proliferation activities against PC3, A549, KB, and HCT116 cancer cell lines. Five of the tested compounds showed enhanced p53-MDM2 binding inhibitory potency and anti-proliferation activities in comparison with that of Nutlin-1. Flow cytometric analysis indicated that compound 7c, one of the most potent p53-MDM2 binding inhibitors with a Ki value of 0.6 μM, showed its ability to arrest cell cycle progression.

Heterocyclic compounds as P2X7 ion channel blockers

The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: 1 wherein R, R1, R2, R3, R4, R5, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer''s disease, etc.